Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study

Background & Aims: Durvalumab plus tremelimumab (STRIDE) has emerged as a first-line systemic treatment option for unresectable hepatocellular carcinoma (HCC). This international multicentre study aimed to evaluate the efficacy and tolerability of STRIDE or durvalumab monotherapy in routine clin...

Полное описание

Библиографические подробности

Главные авторы:	Ciro Celsa, Tiziana Pressiani, Naoshi Nishida, Shadi Mohamad Chamseddine, Ashwini Arvind, Michael Li, Marta Fortuny, Najib Ben Khaled, Massimo Iavarone, Hidenori Toyoda, Ilario Giovanni Rapposelli, Andrea Casadei-Gardini, Caterina Vivaldi, Susanna Ulahannan, Haripriya Andanamala, Bernhard Scheiner, Matthias Pinter, Elena Orlandi, Claudia A.M. Fulgenzi, Giulia F. Manfredi, Pasquale Lombardi, Antonio D’Alessio, Bernardo Stefanini, Rosanna Villani, Francesca Romana Ponziani, Leonardo Stella, Ornella Carminati, Angela Dalia Ricci, Melina Gonzalez, Alba Sparacino, Gabriele Di Maria, Marco Vaccaro, Giuseppe Cabibbo, Calogero Cammà, Maria Reig, Robin K. Kelley, Amit G. Singal, Ahmed O. Kaseb, Masatoshi Kudo, Lorenza Rimassa, David James Pinato
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2026-03-01
Серии:	JHEP Reports
Предметы:	Hepatocellular carcinoma Immunotherapy Durvalumab Tremelimumab Real-world evidence
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2589555925003684
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!